InnoCan Pharma Corporation (CSE:INNO)
Canada · Delayed Price · Currency is CAD 2.440
+0.090 (3.83%)
Sep 17, 2026, 5:16 PM EST
InnoCan Pharma Ratios and Metrics
Market cap in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11 | 30 | 60 | 83 | 54 | 199 | |
Market Cap Growth | -76.98% | -49.98% | -27.47% | 54.74% | -72.99% | 218.14% |
Enterprise Value | 8 | 26 | 56 | 78 | 45 | 191 |
Last Close Price | 2.44 | 6.70 | 13.65 | 20.15 | 13.97 | 52.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 0.33 | 0.83 | 1.42 | 4.61 | 15.50 | 801.47 |
PB Ratio | 1.04 | 2.67 | 5.96 | 14.34 | 6.37 | 17.43 |
P/TBV Ratio | 1.61 | 3.93 | 8.11 | 15.33 | 6.20 | 17.35 |
P/FCF Ratio | - | 45.89 | - | - | - | - |
P/OCF Ratio | - | 44.41 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.24 | 0.71 | 1.32 | 4.32 | 12.89 | 771.51 |
EV/FCF Ratio | - | 39.60 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.23 | 0.11 | 0.00 | 0.01 | 0.01 | 0 |
Debt / FCF Ratio | - | 1.94 | - | - | - | - |
Net Debt / Equity Ratio | -0.64 | -0.70 | -0.71 | -0.88 | -0.79 | -1.23 |
Net Debt / EBITDA Ratio | 1.39 | 4.75 | 4.12 | 1.02 | 0.79 | 1.49 |
Net Debt / FCF Ratio | 3.06 | -12.02 | 3.14 | 0.98 | 0.81 | 1.66 |
Asset Turnover | 2.20 | 2.69 | 3.63 | 1.96 | 0.26 | 0.02 |
Inventory Turnover | 0.94 | 0.98 | 1.28 | 1.17 | 0.55 | 0.16 |
Quick Ratio | 3.78 | 5.63 | 2.48 | 1.79 | 7.10 | 3.15 |
Current Ratio | 5.25 | 7.70 | 4.09 | 2.68 | 9.41 | 3.51 |
Return on Equity (ROE) | -11.82% | -4.47% | -4.59% | -80.07% | -51.05% | -373.46% |
Return on Assets (ROA) | -20.06% | -7.93% | -9.62% | -34.16% | -40.06% | -55.30% |
Return on Invested Capital (ROIC) | -127.30% | 223.57% | 27.80% | -412.03% | - | - |
Return on Capital Employed (ROCE) | -40.80% | -13.70% | -17.80% | -86.50% | -100.30% | -83.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -12.41% | -5.11% | -4.38% | -7.47% | -9.49% | -6.40% |
FCF Yield | -20.01% | 2.18% | -3.81% | -6.28% | -15.36% | -4.25% |
Buyback Yield / Dilution | -1.40% | -3.92% | -8.96% | -3.23% | -10.87% | -38.59% |